Lonza and Antharis Partner to Develop Dual-Payload ADCs for Gastrointestinal Cancers

Lonza's manufacturing infrastructure will be tested against one of the more complex conjugation challenges in oncology biologics, as the contract development and manufacturing organization signs a development partnership with Antharis Therapeutics to advance next-generation dual-payload antibody-drug conjugates targeting gastrointestinal cancers.

Dual-payload ADC platforms introduce compounded process complexity relative to conventional single-payload constructs. Drug-to-antibody ratio control, linker chemistry compatibility, and conjugation site selectivity each carry heightened consequence when two cytotoxic payloads are involved, raising the bar for process validation and in-process analytical controls under 21 CFR Part 211 and ICH Q11 expectations. For QA directors overseeing ADC programs, the partnership signals that CDMOs are moving to absorb that complexity rather than leaving sponsors to resolve it independently.

Antharis is a clinical-stage biotechnology company focused on gastrointestinal oncology. The collaboration with Lonza is structured around development-stage work, with manufacturing scale-up presumably contingent on program progression. Financial terms were not disclosed.

The GI oncology space has seen accelerating ADC activity, with regulatory agencies in the US and EU processing a growing dossier of conjugate submissions. Dual-payload constructs remain largely pre-commercial, meaning the analytical method development and comparability frameworks that will eventually support a BLA or MAA filing are still being defined across the industry. Lonza's early-stage involvement positions the CDMO to shape those frameworks alongside Antharis rather than inherit them at tech transfer.

For plant heads and regulatory affairs leads tracking ADC manufacturing capacity, the partnership reflects a broader trend of CDMOs committing to next-generation conjugation platforms before the regulatory playbook for dual-payload constructs is fully codified, a posture that carries both competitive and compliance risk.

The measurable checkpoint for this program will be the comparability data package generated at the transition from development-scale to GMP manufacturing runs.

Source: Indian Pharma Post via Media4Growth, 14 June 2026.